(7) Maturity Café
Tuesday, September 26
11:30 AM - 03:30 PM
Live in Berlin
Less Details
Over or under 5 years?
Are there currently any practical improvements seen by AI/ML in your plants? Or if not, how do you see it’s applications in the future, how will it help you once you have the data?
If it was a phased approach (e.g. eLogs > eBR > interfaces > pharma 4.0 technologies), which stage was the most difficult and which had the biggest payoff?
For processes that require a high degree of flexibility, have you seen a reduction in flexibility with MES and have the benefits outweighed the loss? (e.g. clinical phase II or III).
Are the technology/quality systems ready for enabling flexible MES solutions for these product stages? What makes them so?
I am an enthusiastic MES site lead with experience in delivering site wide digitalization projects ranging from environmental monitoring, MES and eLogs systems that interface with ERPs LIMS, Data historians etc. My experience in the healthcare and pharmaceutical industry ranges from direct patient care, reagent manufacture, hospital diagnostics and human and animal pharmaceuticals. I have been an IBMS licensed biomedical scientist, worked in QC laboratories and now work to digitalize operations at the Lonza Netherlands Cell and Gene plant which currently includes allogeneic, autologous and mRNA modalities.
My experience with MES systems lies with MODA ES, Lonza’s own next generation MES solution for eBR and eLogs. I work with an interdisciplinary team to bring this solution to the shop floor.
Outside of my core function I enjoy implementing systems to improve efficiency and drive operational improvements. For example, I developed a PowerApp to utilize QR codes to track and report paper batch records across the site, complete with a user account and permissions system, and led a team to ensure its successful deployment.